Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review

References

• Mittoo S, Gelber AC, Christopher-Stine L, et al. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med. 2009;103:1152–1158.
   PubMed Web of Science ®Google Scholar
• Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–748.
   PubMed Web of Science ®Google Scholar
• Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175:705–711.
   PubMed Web of Science ®Google Scholar
• Solomon JJ, Chartrand S, Fischer A. Current approach to connective tissue disease-associated interstitial lung disease. Curr Opin Pulm Med. 2014;20:449–456.
   PubMed Web of Science ®Google Scholar
• Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143:814–824.
   PubMed Web of Science ®Google Scholar
• Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med. 2007;176:691–697.
   PubMed Web of Science ®Google Scholar
• Fischer A, West SG, Swigris JJ, et al. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest. 2010;138:251–256.
   PubMed Web of Science ®Google Scholar
• Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest. 2011;140:1292–1299.
   PubMed Web of Science ®Google Scholar
• Corte TJ, Copley SJ, Desai SR, et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J. 2012;39:661–668.
   PubMed Web of Science ®Google Scholar
• Fischer A, Antoniou KM, Brown KK, et al. “ERS/ATS task force on undifferentiated forms of CTD-ILD”. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;246:976–987.
   Google Scholar
• Hsu E, Shi H, Jordan RM, et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 2011;63:783–794.
   PubMed Web of Science ®Google Scholar
• Peljto AL, Steele MP, Fingerlin TE, et al. The pulmonary fibrosis associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest. 2012;142:1584–1588.
   PubMed Web of Science ®Google Scholar
• Hant FN, Ludwicka-Bradley A, Wang HJ, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J. Rheumatol. 2009;36:773–780.
   PubMed Web of Science ®Google Scholar
• De Carvalho EF, Parra ER, De Souza R, et al. Arterial and interstitial remodelling processes in non-specific interstitial pneumonia: systemic sclerosis versus idiopathic. Histopathology. 2008;53:195–204.
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Khan K, Shiwen X, et al. Fibroblast-specific perturbation of transforming growth factor β signaling provides insight into potential pathogenic mechanisms of scleroderma associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis Rheum. 2008;58:1175–1188.
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Derrett-Smith EC, Khan K, et al. An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high affinity type II transforming growth factor receptor. Am J Respir Crit Care Med. 2011;183:249–261.
   PubMed Web of Science ®Google Scholar
• Bartis D, Mise N, Mahida RY, et al. Epithelial-mesenchymal transition in lung development and disease: does it exist and is it important? Thorax. 2014;69:760–765.
   PubMed Web of Science ®Google Scholar
• Ytterberg AJ, Joshua V, Reynisdottir G, et al. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation. Ann Rheum Dis. 2015;74:1772–1777.
   PubMed Web of Science ®Google Scholar
• Willis VC, Demoruelle MK, Derber LA, et al. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum. 2013;65:2545–2554.
   PubMedGoogle Scholar
• Reynisdottir G, Karimi R, Joshua V, et al. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol. 2014;66:31–39.
   PubMed Web of Science ®Google Scholar
• Rangel-Moreno J, Hartson L, Navarro C, et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Investig. 2006;116:3183–3194.
   PubMed Web of Science ®Google Scholar
• Fischer A, Solomon JJ, Du Bois RM, et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med. 2016;106:1040–1047.
   Google Scholar
• Gizinski AM, Mascolo M, Loucks JL, et al. Rheumatoid arthritis(RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol. 2009;28:611–613.
   PubMed Web of Science ®Google Scholar
• Ascherman DP. Interstitial lung disease in rheumatoid arthritis. Curr Rheumatol Rep. 2010;12:363–369.
   PubMedGoogle Scholar
• Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168:159–166.
   PubMedGoogle Scholar
• MacDonald SL, Rubens MB, Hansell DM, et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances and diagnostic accuracy of thin-section CT. Radiology. 2001;221:600–605.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax. 2003;58:143–148.
   PubMed Web of Science ®Google Scholar
• Desbois AC, Cacoub P. Systemic sclerosis: an update in 2016. Autoimmun Rev. 2016;15:417–426.
   PubMed Web of Science ®Google Scholar
• Marie I. Systemic sclerosis and occupational exposure: towards an extension of legal recognition as occupational disorder in 2014? Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne. 2014;35:631–635.
   PubMed Web of Science ®Google Scholar
• Martin J-E, Broen JC, Carmona FD, et al. Identification of CSK as a systemic sclerosis genetic risk factor through genome wide association study follow-up. Hum Mol Genet. 2012;21:2825–2835.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Gourh P, Shete S, et al. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African- American and Hispanic cases and 1000 controls. Ann Rheum Dis. 2010;69:822–827.
   PubMed Web of Science ®Google Scholar
• Gilchrist FC, Bunn C, Foley PJ, et al. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun. 2001;2:76–81.
   PubMed Web of Science ®Google Scholar
• Shirai Y, Okazaki Y, Inoue Y, et al. Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis: PTX3 and SSc vasculopathy. Arthritis Rheumatol. 2015;67:498–507.
   PubMedGoogle Scholar
• Kawakami T, Ihn H, Xu W, et al. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol. 1998;110:47–51.
   PubMed Web of Science ®Google Scholar
• Parel Y, Aurrand-Lions M, Scheja A, et al. Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum. 2007;56:3459–3467.
   PubMed Web of Science ®Google Scholar
• Luzina IG, Atamas SP, Wise R, et al. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum. 2003;48:2262–2274.
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Massone C. Update on the pathogenesis of Scleroderma: focus on circulating progenitor cells. F1000Res.;5. Pii: F1000 Faculty Rev-723. 2016.
   Google Scholar
• Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002;81:139–153.
   PubMed Web of Science ®Google Scholar
• Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2007;66:754–763.
   PubMed Web of Science ®Google Scholar
• Greidinger EL, Flaherty KT, White B, et al. African American race andantibodies totopoisomerase I are associated with increased severity of scleroderma lung disease. Chest. 1998;114:801–807.
   PubMed Web of Science ®Google Scholar
• Morelli S, Barbieri C, Sgreccia A, et al. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol. 1997;24:81–85.
   PubMed Web of Science ®Google Scholar
• Yanaba K, Hasegawa M, Takehara K, et al. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol. 2004;31:1112–1120.
   PubMed Web of Science ®Google Scholar
• Leslie KO, Trahan S, Gruden J. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med. 2007;28:369–378.
   PubMed Web of Science ®Google Scholar
• Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581–1586.
   PubMed Web of Science ®Google Scholar
• Ryu JH, Krowka MJ, Pellikka PA, et al. Pulmonary hypertension in patients with interstitial lung dis- eases. Mayo Clinic Proc. 2007;82:342–350.
   PubMed Web of Science ®Google Scholar
• Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62:1088–1093.
   PubMed Web of Science ®Google Scholar
• Hachulla E, De Groote P, Gressin V, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum. 2009;60:1831–1839.
   PubMed Web of Science ®Google Scholar
• Sanges S, Launay D, Rhee RL, et al. A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis. 2016;75(8):1457–1465.
   Google Scholar
• Girgis RE, Mathai SC, Krishnan JA, et al. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant. 2005;24:1626–1631.
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–818.
   PubMed Web of Science ®Google Scholar
• Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132:425–434.
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1329.
   PubMed Web of Science ®Google Scholar
• Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum. 2009;60:569–577.
   PubMed Web of Science ®Google Scholar
• Le Pavec J, Girgis RE, Lechtzin N, et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum. 2011;63:2456–2464.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655–2666.
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962–3970.
   PubMed Web of Science ®Google Scholar
• Clements PJ, Tashkin D, Roth M, et al. The scleroderma lung study II (SLS II) shows that both oral cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are efficacious in treating progressive interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). Arthritis Rheum. 2017;67[abstract](Suppl. 10).
   Google Scholar
• Bosello SL, De Luca G, Rucco M, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44:428–436.
   PubMed Web of Science ®Google Scholar
• Jordan S, Distler JH, Maurer B, et al. EUSTAR Rituximab study group). Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188–1194.
   PubMed Web of Science ®Google Scholar
• Khanna D, Saggar R, Mayes MD, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011;63:3540–3546.
   PubMed Web of Science ®Google Scholar
• Fraticelli P, Gabrielli B, Pomponio G, et al. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014;16:R144.
   PubMed Web of Science ®Google Scholar
• Burt RK, Shah SJ, Dill K, et al. Autologous nonmyeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet Lond Engl. 2011;378:498–506.
   PubMed Web of Science ®Google Scholar
• Van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stemcell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311:2490–2498.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35:1322–1328.
   PubMed Web of Science ®Google Scholar
• Doyle JJ, Eliasson AH, Argyros GJ, et al. Prevalence of pulmonary disorders in patients with newly diagnosed rheumatoid arthritis. Clin Rheumatol. 2000;19:217–221.
   PubMed Web of Science ®Google Scholar
• Marigliano B, Soriano A, Margiotta D, et al. Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis. Autoimmun Rev. 2013;12(11):1076–1084.
   PubMed Web of Science ®Google Scholar
• Solomon JJ, Brown KK. Rheumatoid arthritis-associated interstitial lung disease. Open Access Rheumatol. 2012;4:21–31.
   PubMedGoogle Scholar
• Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38–46.
   PubMed Web of Science ®Google Scholar
• Makrygiannakis D, Hermansson M, Ulfgren AK, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis. 2008;67(10):1488–1492.
   PubMed Web of Science ®Google Scholar
• Harlow L, Rosas IO, Gochuico BR, et al. Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum. 2013;65:869–879.
   PubMedGoogle Scholar
• Giles JT, Danoff SK, Sokolove J, et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis. 2014;73:1487–1494.
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J. 2011;37:1411–1417.
   PubMed Web of Science ®Google Scholar
• Zamora-Legoff JA, Krause ML, Crowson CS, et al. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2016 Dec 10;pii: kew391. [Epub ahead of print].
   Google Scholar
• Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40:640–646.
   PubMed Web of Science ®Google Scholar
• Matteson EL, Bongartz T, Ryu JH, et al. Open-label, pilot study of safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheumatol Autoimmune Disord. 2012;2:53–58.
   Google Scholar
• De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol. 2013;40(4):435–446.
   PubMed Web of Science ®Google Scholar
• Kelly C, Saravanan V. Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease. Expert Opin Pharmacother. 2008;9(18):3221–3230.
   PubMed Web of Science ®Google Scholar
• Morisset J, Johnson C, Rich E, et al. Management of myositis-related interstitial lung disease. Chest. 2016;150:1118–1128.
   PubMed Web of Science ®Google Scholar
• Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. 2008;59:677–685.
   PubMed Web of Science ®Google Scholar
• Bonnefoy O, Ferretti G, Calaque O, et al. Serial chest CT findings in interstitial lung disease associated with polymyositis-dermatomyositis. Eur J Radiol. 2004;49:235–244.
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Hozumi H, Kono M, et al. Prognostic factors for myositis-associated interstitial lung disease. PLoS One. 2014;9:e98824.
   PubMed Web of Science ®Google Scholar
• Karadimitrakis S, Plastiras SC, Zormpala A, et al. Chest CT findings in patients with inflammatory myopathy and Jo1 antibodies. Eur J Radiol. 2008;66:27–30.
   PubMed Web of Science ®Google Scholar
• Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum. 2003;32:273–284.
   PubMed Web of Science ®Google Scholar
• Chaisson NF, Paik J, Orbai AM, et al. A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine (Baltimore). 2019;91:220e8.
   Google Scholar
• Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol Publ Soc Bras Pneumol Tisilogia. 2011;37:100–109.
   PubMed Web of Science ®Google Scholar
• Monti S, Montecucco C, Cavagna L. Clinical spectrum of anti-Jo-1-associated disease. Curr Opin Rheumatol. 2017;29(6):612–617.
   PubMed Web of Science ®Google Scholar
• Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164:1182–1185.
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007;46(1):124.
   PubMed Web of Science ®Google Scholar
• Sem M, Molberg O, Lund MB, et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford). 2009;48:968–971.
   PubMed Web of Science ®Google Scholar
• Lambotte O, Kotb R, Maigne G, et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol. 2005;32:1369–1370.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87:210–219.
   PubMed Web of Science ®Google Scholar
• Launay D, Hachulla E, Hatron PY, et al. Pulmonary arterial hypertension: a rare complication of primary Sjogren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore). 2007;86:299–315.
   PubMed Web of Science ®Google Scholar
• Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjogren syndrome. Chest. 2006;130:1489–1495.
   PubMed Web of Science ®Google Scholar
• Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjogren’s syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med. 2005;171:632–638.
   PubMed Web of Science ®Google Scholar
• Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjogren’s syndrome. Ann Rheum Dis. 2000;59:709–712.
   PubMed Web of Science ®Google Scholar
• Flament T, Bigot A, Chaigne B, et al. Pulmonary manifestations of Sjögren’s syndrome. Eur Respir Rev. 2016;25(140):110–123.
   PubMed Web of Science ®Google Scholar
• Papageorgiou A, Voulgarelis M, Tzioufas AG. Clinical picture, outcome and predictive factors of lymphoma in Sjӧgren syndrome. Autoimmun Rev. 2015;14:641–649.
   PubMed Web of Science ®Google Scholar
• Deheinzelin D, Capelozzi VL, Kairalla RA, et al. Interstitial lung disease in primary Sjögren’s syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med. 1996;154:794–799.
   PubMed Web of Science ®Google Scholar
• Roca F, Dominique S, Schmidt J, et al. Interstitial lung disease in primary Sjögren’s syndrome. Autoimmun Rev. 2017;16:48–54.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Seror R, et al. Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology. 2015;54:2230–2238.
   PubMed Web of Science ®Google Scholar
• Nannini C, Jebakumar AJ, Crowson CS, et al. Primary Sjogren’s syndrome 1976–2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open. 2013;3:e003569.
   PubMed Web of Science ®Google Scholar
• Gottenberg J-E, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis. 2013;72:1026–1031.
   PubMed Web of Science ®Google Scholar
• Prakash UB. Respiratory complications in mixed connective tissue disease. Clin Chest Med. 1998;19:733–746.
   PubMed Web of Science ®Google Scholar
• Tani C, Carli L, Vagnani S, et al. The diagnosis and classification of mixed connective tissue disease. J Autoimmun. 2014;48-49:46–49.
   PubMed Web of Science ®Google Scholar
• Gunnarsson R, El-Hage F, Aalokken TM, et al. Associations between anti- Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford). 2016;55:103–108.
   PubMed Web of Science ®Google Scholar
• Bodolay E, Szekanecz Z, Devenyi K, et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford). 2005;44:656–661.
   PubMed Web of Science ®Google Scholar
• Wallace B, Vummidi D, Khanna D. Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. Curr Opin Rheumatol. 2016;28(3):236–245.
   PubMed Web of Science ®Google Scholar
• Pego-Reigosa JM, Medeiros DA, Isenberg DA. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res Clin Rheumatol. 2009;23:469–480.
   PubMed Web of Science ®Google Scholar
• Cervera R, Serrano R, Pons-Estel GJ, et al. Euro-Phospholipid Project Group (European forum on antiphospholipid antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74(6):1011–1018.
   PubMed Web of Science ®Google Scholar
• Carette S, Macher AM, Nussbaum A, et al. Severe, acute pulmonary disease in patients with systemic lupus erythematosus: ten years of experience at the National Institutes of Health. Semin Arthritis Rheum. 1984;14:52–59.
   PubMed Web of Science ®Google Scholar
• Zamora MR, Warner ML, Tuder R, et al. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore). 1997;76:192–202.
   PubMed Web of Science ®Google Scholar
• Watts RA, Mahr A, Mohammad AJ, et al. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015;30(Suppl 1):i14–22.
   PubMed Web of Science ®Google Scholar
• Thickett DR, Richter AG, Nathani N, et al. Pulmonary manifestations of anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis. Rheumatology. 2006;45:261–268.
   PubMed Web of Science ®Google Scholar
• Ravindran V, Watts RA. Pulmonary haemorrhage in ANCA associated vasculitis. Rheumatology. 2010;49:1410–1412.
   PubMed Web of Science ®Google Scholar
• Mahmoud S, Ghosh S, Farver C, et al. Pulmonary vasculitis: spectrum of imaging appearances. Radiol Clin N Am. 2016;54:1097–1118.
   PubMed Web of Science ®Google Scholar
• Castañer E, Alguersuari A, Andreu M, et al. Imaging findings in pulmonary vasculitis. Semin Ultrasound CT MR. 2012;33:567–579.
   PubMed Web of Science ®Google Scholar
• Flores-Suárez LF, Alba MA, Mateos-Toledo H, et al. Pulmonary involvement in systemic vasculitis. Curr Rheumatol Rep. 2017;19(9):56.
   PubMed Web of Science ®Google Scholar
• Comarmond C, Crestani B, Tazi A, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. A series of 49 patients and review of the literature. Medicine. 2014;93:340–349.
   PubMed Web of Science ®Google Scholar
• Miura Y, Saito T, Fujita K, et al. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31:235–238.
   PubMed Web of Science ®Google Scholar
• Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med. 2013;5:205ra136.
   PubMed Web of Science ®Google Scholar
• Huaringa AJ, Francis WH. Pulmonary alveolar proteinosis: a case report and world literature review. Respirol Case Rep. 2016;4(6):e00201.
   PubMed Web of Science ®Google Scholar
• Papiris SA, Tsirigotis P, Kolilekas L, et al. Pulmonary alveolar proteinosis: time to shift? Expert Rev Respir Med. 2015;9(3):337–349.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Trapnell BC. Pulmonary alveolar proteinosis syndrome. Clin Chest Med. 2016;37(3):431–440.
   PubMed Web of Science ®Google Scholar
• Kelly C, Iqbal K, Iman-Gutierrez L, et al. Lung involvement in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol. 2016;30:870–888.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Boiardi L, Sallì S, et al. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. Expert Rev Clin Immunol. 2013;9(7):649–657.
   PubMed Web of Science ®Google Scholar
• Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000;15:373–381.
   PubMed Web of Science ®Google Scholar
• Alarcon GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127:356–364.
   PubMed Web of Science ®Google Scholar
• Parry SD, Barbatzas C, Peel ET, et al. Sulphasalazine and lung toxicity. Eur Respir J. 2002;19:756–764.
   PubMed Web of Science ®Google Scholar
• Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41:256–264.
   PubMed Web of Science ®Google Scholar
• Hadjinicolaou AV, Nisar MK, Bhagat S, et al. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases e a systematic literature review. Rheumatol Oxf Ord. 2011;50:2297–2305.
   PubMed Web of Science ®Google Scholar
• Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Sem Arthritis Rheum. 2014;43(5):613–626.
   PubMed Web of Science ®Google Scholar
• De Lauretis A, Veeraraghavan S, Renzoni E. Review series: aspects of interstitial lung disease: connective tissue disease associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011;8:53–82.
   PubMed Web of Science ®Google Scholar
• Hallowell RW, Horton MR. Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced. Drugs. 2014;74:443–450.
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456–473.
   PubMed Web of Science ®Google Scholar
• Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19:353–359.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987–997.
   PubMed Web of Science ®Google Scholar
• Kawashiri SY, Kawakami A, Sakamoto N, et al. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int. 2012;32:4023–4026.
   PubMed Web of Science ®Google Scholar
• Wendling D, Vidon C, Godfrin-Valnet M, et al. Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis. Jone Bone Spine. 2013;80:670–671.
   PubMed Web of Science ®Google Scholar
• Wada T, Akiyama Y, Yokota K, et al. A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept. Nihon Rinsho Meneki Gakkai Kaishi. 2012;35:433–438.
   PubMedGoogle Scholar